Search Results - "Bruneel, E"

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO) by Bompas, E., Le Cesne, A., Tresch-Bruneel, E., Lebellec, L., Laurence, V., Collard, O., Saada-Bouzid, E., Isambert, N., Blay, J.Y., Amela, E.Y., Salas, S., Chevreau, C., Bertucci, F., Italiano, A., Clisant, S., Penel, N.

“…There is no consensual treatment of locally advanced or metastatic chordomas. We conducted a multicenter, open-label, uncontrolled phase II trial of sorafenib…”
Get full text

Cohort Profile: Effective Perinatal Intensive Care in Europe (EPICE) very preterm birth cohort by Zeitlin, Jennifer, Maier, Rolf F, Cuttini, Marina, Aden, Ulrika, Boerch, Klaus, Gadzinowski, Janusz, Jarreau, Pierre-Henri, Lebeer, Jo, Norman, Mikael, Pedersen, Pernille, Petrou, Stavros, Pfeil, Johanna M, Toome, Liis, van Heijst, Arno, Van Reempts, Patrick, Varendi, Heili, Barros, Henrique, Draper, Elizabeth S

Get full text

Parents’ ratings of post-discharge healthcare for their children born very preterm and their suggestions for improvement: a European cohort study by Seppänen, Anna-Veera, Sauvegrain, Priscille, Draper, Elizabeth S., Toome, Liis, El Rafei, Rym, Petrou, Stavros, Barros, Henrique, Zimmermann, Luc J. I., Cuttini, Marina, Zeitlin, Jennifer

“…Background Follow-up of very preterm infants is essential for reducing risks of health and developmental problems and relies on parental engagement. We…”
Get full text

Health-related quality of life of children born very preterm: a multinational European cohort study by Kim, Sung Wook, Andronis, Lazaros, Seppänen, Anna-Veera, Aubert, Adrien M., Barros, Henrique, Draper, Elizabeth S., Sentenac, Mariane, Zeitlin, Jennifer, Petrou, Stavros

“…Purpose This study aims to (1) describe the health-related quality of life (HRQoL) outcomes experienced by children born very preterm (28–31 weeks’ gestation)…”
Get full text

Motor‐related health care for 5‐year‐old children born extremely preterm with movement impairments by Costa, Raquel, Aubert, Adrien M., Seppänen, Anna‐Veera, Ådén, Ulrika, Sarrechia, Lemke, Zemlin, Michael, Cuttini, Marina, Männamaa, Mairi, Pierrat, Véronique, Heijst, Arno, Barros, Henrique, Johnson, Samantha, Zeitlin, Jennifer, Lebeer, J, Van Reempts, P, Bruneel, E, Cloet, E, Oostra, A, Ortibus, E, Boerch, K, Pedersen, P, Toome, L, Varendi, H, Ancel, P. Y., Burguet, A, Jarreau, P. H., Nuytten, A, Truffert, P, Maier, R. F., Misselwitz, B, Wohlers, L, Croci, I, Carnielli, V, Ancora, G, Faldella, G, Ferrari, F, Koopman‐Esseboom, C, Gadzinowski, J, Mazela, J, Montgomery, A, Pikuła, T, Rodrigues, C, Draper, E. S., Fenton, A, Mader, S, Thiele, N, Pfeil, J. M., Petrou, S, Kim, S. W., Andronis, L, Bonnet, C, El Rafei, R

“…Aim To (1) determine the proportion of 5‐year‐old children born extremely preterm (EPT) with movement difficulties including cerebral palsy (CP) and the…”
Get full text

Risk factors for cerebral palsy and movement difficulties in 5-year-old children born extremely preterm by Aubert, Adrien M., Costa, Raquel, Johnson, Samantha, Ådén, Ulrika, Cuttini, Marina, Koopman-Esseboom, Corine, Lebeer, Jo, Varendi, Heili, Zemlin, Michael, Pierrat, Véronique, Zeitlin, Jennifer

“…Background Motor impairment is common after extremely preterm (EPT, <28 weeks’ gestational age (GA)) birth, with cerebral palsy (CP) affecting about 10% of…”
Get full text

Prediction of movement difficulties at 5 years from parent report at 2 years in children born extremely preterm by Costa, Raquel, Aubert, Adrien M., Seppänen, Anna‐Veera, Ådén, Ulrika, Sarrechia, Iemke, Zemlin, Michael, Cuttini, Marina, Männamaa, Mairi, Pierrat, Véronique, Heijst, Arno, Barros, Henrique, Zeitlin, Jennifer, Johnson, Samantha, Lebeer, J, Sarrechia, I, Van Reempts, P, Bruneel, E, Cloet, E, Oostra, A, Ortibus, E, Boerch, K, Pedersen, P, Toome, L, Varendi, H, Männamaa, M, Ancel, P Y, Burguet, A, Jarreau, P H, Pierrat, V, Nuytten, A, Maier, R F, Zemlin, M, Misselwitz, B, Wohlers, L, Cuttini, M, Croci, I, Carnielli, V, Ancora, G, Sansavini, A., Faldella, G, Ferrari, F, Heijst, A, Koopman‐Esseboom, C, Gadzinowski, J, Mazela, J, Montgomery, A, Pikuła, T, Barros, H, Costa, R, Rodrigues, C, Aden, U, Draper, E S, Fenton, A, Johnson, S J, Mader, S, Thiele, N, Pfeil, J M, Petrou, S, Kim, S W, Andronis, L, Coordination, Inserm, Zeitlin, J, Aubert, A M, Bonnet, C, El Rafei, R, Seppänen, A V

“…Aim To assess the predictive validity of parent‐reported gross motor impairment (GMI) at age 2 years to detect significant movement difficulties at age 5 years…”
Get full text

Economic costs at age five associated with very preterm birth: multinational European cohort study by Kim, Sung Wook, Andronis, Lazaros, Seppänen, Anna-Veera, Aubert, Adrien M., Zeitlin, Jennifer, Barros, Henrique, Draper, Elizabeth S., Petrou, Stavros

“…Background This study aims to estimate the economic costs of care provided to children born very preterm and extremely preterm across 11 European countries,…”
Get full text

Crystallization and visible-near-infrared luminescence of Bi-doped gehlenite glass by Majerová, M, Klement, R, Prnová, A, Kraxner, J, Bruneel, E, Galusek, D

“…Gehlenite glass microspheres, doped with a different concentration of Bi ions (0.5, 1, 3 mol%), were prepared by a combination of solid-state reaction followed…”
Get full text

Role of shaping in the preparation of heterogeneous catalysts: Tableting and slip-casting of oxidation catalysts by Baldovino-Medrano, V.G., Le, M.T., Van Driessche, I., Bruneel, E., Alcázar, C., Colomer, M.T., Moreno, R., Florencie, A., Farin, B., Gaigneaux, E.M.

“…•Shaping of bismuth molybdate and vanadium–aluminum mixed (hydr)oxide catalysts was investigated.•Graphite was demonstrated to be an effective shaping agent…”
Get full text

Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients by Kakkos, A., Bresson, L., Hudry, D., Cousin, S., Lervat, C., Bogart, E., Meurant, J.P., El Bedoui, S., Decanter, G., Hannebicque, K., Regis, C., Hamdani, A., Penel, N., Tresch-Bruneel, E., Narducci, F.

“…Totally implantable venous access port systems are widely used in oncology, with frequent complications that sometimes necessitate device removal. The aim of…”
Get full text

The early educational environment at five years of age in a European cohort of children born very preterm: challenges and opportunities for research by Smith-Longee, Alyssa, Johnson, Samantha, Aubert, Adrien M, Seppänen, Anna-Veera, Pierrat, Veronique, Zemlin, Michael, Lebeer, Jo, Sarrechia, Iemke, Siljehav, Veronica, Zeitlin, Jennifer, Sentenac, Mariane

“…Early childhood education offers opportunities for stimulation in multiple developmental domains and its positive impact on long-term outcomes and wellbeing…”
Get full text

Capnocytophaga canimorsus as a cause of spontaneous Gram-negative bacilli community-acquired meningitis by Amara, M., Zappella, N., Bruneel, E., Courboulès, C., Ung, N., Bayle, P., Gydé, E., Bruneel, F., Bédos, J.-P., Pangon, B.

Get full text

How to report toxicity associated with targeted therapies? by Cabarrou, B., Boher, J.M., Bogart, E., Tresch-Bruneel, E., Penel, N., Ravaud, A., Escudier, B., Mahier Ait-Oukhatar, C., Delord, J.P., Roché, H., Filleron, T.

“…In the era of personalized medicine, molecularly targeted therapies (MTT) have modified the outcome of some cancer types. The price of tumor control needs to…”
Get full text

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours by Adenis, A, Ray-Coquard, I, Italiano, A, Chauzit, E, Bui-Nguyen, B, Blay, J-Y, Tresch-Bruneel, E, Fournier, C, Clisant, S, Amela, E Y, Cassier, P A, Molimard, M, Penel, N

“…Background: Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic…”
Get full text

Synthesis and thermal expansion of ZrO2/ZrW2O8 composites by LOMMENS, P, DE MEYER, C, BRUNEEL, E, DE BUYSSER, K, VAN DRIESSCHE, I, HOSTE, S

“…In this work, a ceramic composite of ZrW2O8 and ZrO2 was synthesized, in order to investigate the possibility of compensating the positive thermal expansion of…”
Get full text

Statistical controversies in clinical research: should schedules of tumor size assessments be changed? by Filleron, T., Kouokam, W., Gilhodes, J., Duhamel, A., Penel, N., Joly, F., Tresch-Bruneel, E., Kramar, A., Houédé, N.

“…Time to progression (TTP) is often used as a primary end point in phase II clinical trials. Since the actual date of nadir and progression is never known, most…”
Get full text

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours by ADENIS, A, RAY-COQUARD, I, CASSIER, P. A, MOLIMARD, M, PENEL, N, ITALIANO, A, CHAUZIT, E, BUI-NGUYEN, B, BLAY, J.-Y, TRESCH-BRUNEEL, E, FOURNIER, C, CLISANT, S, AMELA, E. Y

“…Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both…”
Get full text

Can hormonal replacement therapy be a solution for postmenopausal women with nocturia? by Pauwaert, K., Goessaert, A-S., Bruneel, E., Ghijselings, L., Depypere, H., Everaert, K.

Get full text

An unusual inguinal hernia by Monnier, S, Chevreau, G, Bruneel, E, Blanc, C, Meckenstock, R, Therby, A, Belan, A Greder, Amara, M

Get full text